Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joke de Boer

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Acta Dermato-Venereologica|January 31, 2022
Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic DermatitisRoselie E Achten, Chantal Van Luijk, Lisa Van der Rijst, et al.
Clinical and Translational Allergy|January 27, 2023
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface diseaseRoselie Achten, Judith Thijs, Marlot van der Wal, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|February 9, 2024
Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapyRoselie Achten, Judith Thijs, Marlot van der Wal, et al.
Arthritis Care & Research|April 3, 2025
Monitoring of Juvenile Idiopathic Arthritis-Associated Uveitis in Long-Term Disease Remission: Consensus-Based Recommendations From the Multinational Interdisciplinary Working Group for Uveitis in ChildhoodIvan Foeldvari, Ameenat Solebo, Harry Petrushkin, et al.
Arthritis Care & Research|May 31, 2022
New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Chronic Anterior UveitisIvan Foeldvari, Ilaria Maccora, Harry Petrushkin, et al.
Expert Review of Clinical Immunology|May 5, 2026
What is the best way to plan a 12-months clinical drug trial in JIA associated uveitisIvan Foeldvari, Ameenat Solebo, Sheila T Angeles-Han, et al.
Annals of the Rheumatic Diseases|March 30, 2018
Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiativeTamas Constantin, Ivan Foeldvari, Jordi Anton, et al.
Pediatric Rheumatology Online Journal|April 8, 2021
Dutch patients, caregivers and healthcare professionals generate first nationwide research agenda for juvenile idiopathic arthritisAnouk Verwoerd, Wineke Armbrust, Katherine Cowan, et al.
Pediatric Rheumatology Online Journal|October 3, 2019
Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)Ivan Foeldvari, Jens Klotsche, Gabriele Simonini, et al.
Pediatric Rheumatology Online Journal|February 13, 2020
Correction to: Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)Ivan Foeldvari, Jens Klotsche, Gabriele Simonini, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Acta Dermato-Venereologica|January 31, 2022
Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic DermatitisRoselie E Achten, Chantal Van Luijk, Lisa Van der Rijst, et al.
Clinical and Translational Allergy|January 27, 2023
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface diseaseRoselie Achten, Judith Thijs, Marlot van der Wal, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|February 9, 2024
Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapyRoselie Achten, Judith Thijs, Marlot van der Wal, et al.
Arthritis Care & Research|April 3, 2025
Monitoring of Juvenile Idiopathic Arthritis-Associated Uveitis in Long-Term Disease Remission: Consensus-Based Recommendations From the Multinational Interdisciplinary Working Group for Uveitis in ChildhoodIvan Foeldvari, Ameenat Solebo, Harry Petrushkin, et al.
Arthritis Care & Research|May 31, 2022
New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Chronic Anterior UveitisIvan Foeldvari, Ilaria Maccora, Harry Petrushkin, et al.
Expert Review of Clinical Immunology|May 5, 2026
What is the best way to plan a 12-months clinical drug trial in JIA associated uveitisIvan Foeldvari, Ameenat Solebo, Sheila T Angeles-Han, et al.
Annals of the Rheumatic Diseases|March 30, 2018
Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiativeTamas Constantin, Ivan Foeldvari, Jordi Anton, et al.
Pediatric Rheumatology Online Journal|April 8, 2021
Dutch patients, caregivers and healthcare professionals generate first nationwide research agenda for juvenile idiopathic arthritisAnouk Verwoerd, Wineke Armbrust, Katherine Cowan, et al.
Pediatric Rheumatology Online Journal|October 3, 2019
Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)Ivan Foeldvari, Jens Klotsche, Gabriele Simonini, et al.
Pediatric Rheumatology Online Journal|February 13, 2020
Correction to: Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)Ivan Foeldvari, Jens Klotsche, Gabriele Simonini, et al.
Pageof 4